xml version="1.0" ? jnj-20220125

0000200406false00002004062022-01-252022-01-250000200406us-gaap:CommonStockMember2022-01-252022-01-250000200406jnj:A0.650NotesDue2024Member2022-01-252022-01-250000200406jnj:A5.50NotesDue2024Member2022-01-252022-01-250000200406jnj:A1.150NotesDue2028Member2022-01-252022-01-250000200406jnj:A1.650NotesDue2035Member2022-01-252022-01-25

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): 

January 25, 2022 

Johnson & Johnson 

 (Exact name of registrant as specified in its charter)

[DATA_TABLE_REMOVED]

One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 

(Address of Principal Executive Offices)

 (Zip Code) 

Registrant's telephone number, including area code:

732-524-0400 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17

 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17

 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

[DATA_TABLE_REMOVED]

Item 2.02 Results of Operations and Financial Condition

On January 25, 2022, Johnson & Johnson issued the attached press release announcing its sales and earnings for the fourth quarter and full year ended January 2, 2022.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. 

[DATA_TABLE_REMOVED]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

[DATA_TABLE_REMOVED]